MTT: Marfan Treatment Trialists' Collaboration
Established in 2012
Data from approximately 2,300 participants
Marfan syndrome is a genetic disorder of connective tissue which is associated with a substantial risk of serious cardiovascular complications. A number of trials of novel therapies have been established, all of which aim to study the benefits (or harms) of these treatments in patients with Marfan syndrome.
In 2012, in collaboration with Dr Alex Pitcher in the Department of Cardiovascular Medicine in Oxford, the CTSU established the Marfan Treatment Trialists’ (MTT) Collaboration, involving trialists, meta-analysts, statisticians, clinicians and basic scientists, with the aim of conducting a collaborative overview (or meta-analysis) of individual patient data from all trials of angiotensin receptor blockers in Marfan syndrome worldwide. A protocol for the meta-analysis was written by the group prior to the results of the main trials being known, and was published in American Heart Journal (view here).
The meta-analysis, which is expected to include individual patient data from over 2000 participants, will provide an overview of all of the available evidence, and will allow important questions about the treatment of Marfan Syndrome to be studied.